

1. *Staphylococcus aureus* (10⁷ CFU/g)
 2. *Escherichia coli* (10⁶ CFU/g)
 3. *Salmonella enterica* (10⁵ CFU/g)
 4. *Listeria monocytogenes* (10⁵ CFU/g)
 5. *Campylobacter jejuni* (10⁶ CFU/g)
 6. *Yersinia enterocolitica* (10⁵ CFU/g)
 7. *Shigella flexneri* (10⁵ CFU/g)
 8. *Enterobacteriaceae* (10⁷ CFU/g)
 9. *Acinetobacter baumannii* (10⁵ CFU/g)
 10. *Pseudomonas aeruginosa* (10⁶ CFU/g)
 11. *Klebsiella pneumoniae* (10⁶ CFU/g)
 12. *Moraxella catarrhalis* (10⁵ CFU/g)
 13. *Neisseria meningitidis* (10⁵ CFU/g)
 14. *Streptococcus pneumoniae* (10⁵ CFU/g)
 15. *Haemophilus influenzae* (10⁵ CFU/g)
 16. *Mycoplasma pneumoniae* (10⁵ CFU/g)
 17. *Chlamydia pneumoniae* (10⁵ CFU/g)
 18. *Coxsackievirus B1* (10⁵ CFU/g)
 19. *Adenovirus* (10⁵ CFU/g)
 20. *Rotavirus* (10⁵ CFU/g)
 21. *Parvovirus B19* (10⁵ CFU/g)
 22. *Human coronavirus HKU-1* (10⁵ CFU/g)
 23. *Human coronavirus NL63* (10⁵ CFU/g)
 24. *Human coronavirus 229E* (10⁵ CFU/g)
 25. *Human coronavirus OC-42* (10⁵ CFU/g)
 26. *Human coronavirus HKU-229E* (10⁵ CFU/g)
 27. *Human coronavirus NL63* (10⁵ CFU/g)
 28. *Human coronavirus HKU-1* (10⁵ CFU/g)
 29. *Human coronavirus NL63* (10⁵ CFU/g)
 30. *Human coronavirus HKU-1* (10⁵ CFU/g)
 31. *Human coronavirus NL63* (10⁵ CFU/g)
 32. *Human coronavirus HKU-1* (10⁵ CFU/g)
 33. *Human coronavirus NL63* (10⁵ CFU/g)
 34. *Human coronavirus HKU-1* (10⁵ CFU/g)
 35. *Human coronavirus NL63* (10⁵ CFU/g)
 36. *Human coronavirus HKU-1* (10⁵ CFU/g)
 37. *Human coronavirus NL63* (10⁵ CFU/g)
 38. *Human coronavirus HKU-1* (10⁵ CFU/g)
 39. *Human coronavirus NL63* (10⁵ CFU/g)
 40. *Human coronavirus HKU-1* (10⁵ CFU/g)
 41. *Human coronavirus NL63* (10⁵ CFU/g)
 42. *Human coronavirus HKU-1* (10⁵ CFU/g)
 43. *Human coronavirus NL63* (10⁵ CFU/g)
 44. *Human coronavirus HKU-1* (10⁵ CFU/g)
 45. *Human coronavirus NL63* (10⁵ CFU/g)
 46. *Human coronavirus HKU-1* (10⁵ CFU/g)
 47. *Human coronavirus NL63* (10⁵ CFU/g)
 48. *Human coronavirus HKU-1* (10⁵ CFU/g)
 49. *Human coronavirus NL63* (10⁵ CFU/g)
 50. *Human coronavirus HKU-1* (10⁵ CFU/g)
 51. *Human coronavirus NL63* (10⁵ CFU/g)
 52. *Human coronavirus HKU-1* (10⁵ CFU/g)
 53. *Human coronavirus NL63* (10⁵ CFU/g)
 54. *Human coronavirus HKU-1* (10⁵ CFU/g)
 55. *Human coronavirus NL63* (10⁵ CFU/g)
 56. *Human coronavirus HKU-1* (10⁵ CFU/g)
 57. *Human coronavirus NL63* (10⁵ CFU/g)
 58. *Human coronavirus HKU-1* (10⁵ CFU/g)
 59. *Human coronavirus NL63* (10⁵ CFU/g)
 60. *Human coronavirus HKU-1* (10⁵ CFU/g)
 61. *Human coronavirus NL63* (10⁵ CFU/g)
 62. *Human coronavirus HKU-1* (10⁵ CFU/g)
 63. *Human coronavirus NL63* (10⁵ CFU/g)
 64. *Human coronavirus HKU-1* (10⁵ CFU/g)
 65. *Human coronavirus NL63* (10⁵ CFU/g)
 66. *Human coronavirus HKU-1* (10⁵ CFU/g)
 67. *Human coronavirus NL63* (10⁵ CFU/g)
 68. *Human coronavirus HKU-1* (10⁵ CFU/g)
 69. *Human coronavirus NL63* (10⁵ CFU/g)
 70. *Human coronavirus HKU-1* (10⁵ CFU/g)
 71. *Human coronavirus NL63* (10⁵ CFU/g)
 72. *Human coronavirus HKU-1* (10⁵ CFU/g)
 73. *Human coronavirus NL63* (10⁵ CFU/g)
 74. *Human coronavirus HKU-1* (10⁵ CFU/g)
 75. *Human coronavirus NL63* (10⁵ CFU/g)
 76. *Human coronavirus HKU-1* (10⁵ CFU/g)
 77. *Human coronavirus NL63* (10⁵ CFU/g)
 78. *Human coronavirus HKU-1* (10⁵ CFU/g)
 79. *Human coronavirus NL63* (10⁵ CFU/g)
 80. *Human coronavirus HKU-1* (10⁵ CFU/g)
 81. *Human coronavirus NL63* (10⁵ CFU/g)
 82. *Human coronavirus HKU-1* (10⁵ CFU/g)
 83. *Human coronavirus NL63* (10⁵ CFU/g)
 84. *Human coronavirus HKU-1* (10⁵ CFU/g)
 85. *Human coronavirus NL63* (10⁵ CFU/g)
 86. *Human coronavirus HKU-1* (10⁵ CFU/g)
 87. *Human coronavirus NL63* (10⁵ CFU/g)
 88. *Human coronavirus HKU-1* (10⁵ CFU/g)
 89. *Human coronavirus NL63* (10⁵ CFU/g)
 90. *Human coronavirus HKU-1* (10⁵ CFU/g)
 91. *Human coronavirus NL63* (10⁵ CFU/g)
 92. *Human coronavirus HKU-1* (10⁵ CFU/g)
 93. *Human coronavirus NL63* (10⁵ CFU/g)
 94. *Human coronavirus HKU-1* (10⁵ CFU/g)
 95. *Human coronavirus NL63* (10⁵ CFU/g)
 96. *Human coronavirus HKU-1* (10⁵ CFU/g)
 97. *Human coronavirus NL63* (10⁵ CFU/g)
 98. *Human coronavirus HKU-1* (10⁵ CFU/g)
 99. *Human coronavirus NL63* (10⁵ CFU/g)
 100. *Human coronavirus HKU-1* (10⁵ CFU/g)

My residence, post office address and citizenship are as stated below, next to my name.

A METHOD AND APPARATUS FOR SWITCHING DATA OF DIFFERENT PROTOCOLS

 x is attached hereto.
 was filed on _____ as
 _____ United States Application Number _____
 _____ or PCT International Application Number _____
 _____ and was amended on _____.
 (if applicable)

I acknowledge the duty to disclose all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

<u>Prior Foreign Application(s)</u>			<u>Priority Claimed</u>	
<u>(Number)</u>	<u>(Country)</u>	<u>(Foreign Filing Date)</u>	<u>Yes</u>	<u>No</u>
<u>(Number)</u>	<u>(Country)</u>	<u>(Foreign Filing Date)</u>	<u>Yes</u>	<u>No</u>
<u>(Number)</u>	<u>(Country)</u>	<u>(Foreign Filing Date)</u>	<u>Yes</u>	<u>No</u>
<u>(Number)</u>	<u>(Country)</u>	<u>(Foreign Filing Date)</u>	<u>Yes</u>	<u>No</u>

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

<u>60/258,760</u>	<u>December 30, 2000</u>
Application Number	(Filing Date)

_____	_____
Application Number	(Filing Date)

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

_____	_____	_____
Application Number	Filing Date	Status -- patented, pending, abandoned

_____	_____	_____
Application Number	Filing Date	Status -- patented, pending, abandoned

I hereby appoint the persons listed on Appendix A hereto (which is incorporated by reference and a part of this document) as my respective patent attorneys and patent agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith.

Send correspondence to Gregg A. Peacock, Reg. No. 45,001, BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN LLP, 12400 Wilshire Boulevard 7th Floor, Los Angeles, California 90025 and direct telephone calls to Gregg A. Peacock, Reg. No. 45,001, (512) 330-0844.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Sole/First Inventor David Stiles

Inventor's Signature _____

Date _____

Residence Los Gatos, California

(City, State)


Citizenship USA

(Country)

Post Office Address 21108 Brush Road

Los Gatos, California 95033

Full Name of Joint/Second Inventor Gerald W. Neufeld

Inventor's Signature 

Date Mar 29 / 01

Residence Los Altos, CA 94024

(City, State)

Citizenship Canada

(Country)

Post Office Address 675 Greenview Place

Los Altos, CA 94024

FILED

APPENDIX A

William E. Alford, Reg. No. 37,764; Farzad E. Amini, Reg. No. 42,261; William Thomas Babbitt, Reg. No. 39,591; Carol F. Barry, Reg. No. 41,600; Jordan Michael Becker, Reg. No. 39,602; Lisa N. Benado, Reg. No. 39,995; Bradley J. Berezna, Reg. No. 33,474; Michael A. Bernadicou, Reg. No. 35,934; Roger W. Blakely, Jr., Reg. No. 25,831; R. Alan Burnett, Reg. No. 46,149; Gregory D. Caldwell, Reg. No. 39,926; Thomas M. Coester, Reg. No. 39,637; Donna Jo Coningsby, Reg. No. 41,684; Florin Corie, Reg. No. 46,244; Dennis M. deGuzman, Reg. No. 41,702; Stephen M. De Klerk, Reg. No. 46,503; Michael Anthony DeSanctis, Reg. No. 39,957; Daniel M. De Vos, Reg. No. 37,813; Harish C. Dhingra, Reg. No. 38,856; Justin M. Dillon, Reg. No. 42,486; Sanjeet Dutta, Reg. No. 46,145; Matthew C. Fagan, Reg. No. 37,542; Tarek N. Fahmi, Reg. No. 41,402; George Fountain, Reg. No. 37,374; James Y. Go, Reg. No. 40,621; James A. Henry, Reg. No. 41,064; Libby N. Ho, Reg. No. 46,774; Willmore F. Holbrow III, Reg. No. 41,845; Sheryl Sue Holloway, Reg. No. 37,850; George W. Hoover II, Reg. No. 32,992; Eric S. Hyman, Reg. No. 30,139; William W. Kidd, Reg. No. 31,772; Sang Hui Kim, Reg. No. 40,450; Walter T. Kim, Reg. No. 42,731; Eric T. King, Reg. No. 44,188; George Brian Leavell, Reg. No. 45,436; Kurt P. Leyendecker, Reg. No. 42,799; Gordon R. Lindeen III, Reg. No. 33,192; Jan Carol Little, Reg. No. 41,181; Robert G. Litts, Reg. No. 46,876; Joseph Lutz, Reg. No. 43,765; Michael J. Mallie, Reg. No. 36,591; Andre L. Marais, under 37 C.F.R. § 10.9(b); Paul A. Mendonsa, Reg. No. 42,879; Clive D. Menezes, Reg. No. 45,493; Richard A. Nakashima, Reg. No. 42,023; Chun M. Ng, Reg. No. 36,878; Thien T. Nguyen, Reg. No. 43,835; Thinh V. Nguyen, Reg. No. 42,034; Dennis A. Nicholls, Reg. No. 42,036; Robert B. O'Rourke, Reg. No. 46,972; Daniel E. Ovanezian, Reg. No. 41,236; Kenneth B. Paley, Reg. No. 38,989; Gregg A. Peacock, Reg. No. 45,001; Marina Portnova, Reg. No. 45,750; William F. Ryann, Reg. No. 44,313; James H. Salter, Reg. No. 35,668; William W. Schaal, Reg. No. 39,018; James C. Scheller, Reg. No. 31,195; Jeffrey Schubert, Reg. No. 43,089; George P. Simion, Reg. No. 47,089; Jeffrey Sam Smith, Reg. No. 39,377; Maria McCormack Sobrino, Reg. No. 31,639; Stanley W. Sokoloff, Reg. No. 25,128; Judith A. Szepesi, Reg. No. 39,393; Vincent P. Tassinari, Reg. No. 42,179; Edwin H. Taylor, Reg. No. 25,129; John F. Travis, Reg. No. 43,203; Joseph A. Twarowski, Reg. No. 42,191; Tom Van Zandt, Reg. No. 43,219; Lester J. Vincent, Reg. No. 31,460; Glenn E. Von Tersch, Reg. No. 41,364; John Patrick Ward, Reg. No. 40,216; Mark L. Watson, Reg. No. 46,322; Thomas C. Webster, Reg. No. 46,154; and Norman Zafman, Reg. No. 26,250; my patent attorneys, and Firasat Ali, Reg. No. 45,715; Thomas S. Ferrill, Reg. No. 42,532; Charles P. Landrum, Reg. No. 46,855; and Raul Martinez, Reg. No. 46,904, my patent agents, of BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN LLP, with offices located at 12400 Wilshire Boulevard, 7th Floor, Los Angeles, California 90025, telephone (310) 207-3800, and James R. Thein, Reg. No. 31,710, my patent attorney with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith.

APPENDIX B

Title 37, Code of Federal Regulations, Section 1.56 Duty to Disclose Information Material to Patentability

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

(1) Prior art cited in search reports of a foreign patent office in a counterpart application, and

(2) The closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

(b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

(1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or

(2) It refutes, or is inconsistent with, a position the applicant takes in:

(i) Opposing an argument of unpatentability relied on by the Office, or

(ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

(c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:

(1) Each inventor named in the application;

(2) Each attorney or agent who prepares or prosecutes the application; and

(3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.

(d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.

[illegible]

My residence, post office address and citizenship are as stated below, next to my name.

A METHOD AND APPARATUS FOR SWITCHING DATA OF DIFFERENT PROTOCOLS

 x is attached hereto.
 was filed on _____ as
 _____ United States Application Number _____
 _____ or PCT International Application Number _____
 _____ and was amended on _____.
 (if applicable)

I acknowledge the duty to disclose all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

<u>Prior Foreign Application(s)</u>			<u>Priority Claimed</u>	
<u>(Number)</u>	<u>(Country)</u>	<u>(Foreign Filing Date)</u>	<u>Yes</u>	<u>No</u>
<u>(Number)</u>	<u>(Country)</u>	<u>(Foreign Filing Date)</u>	<u>Yes</u>	<u>No</u>
<u>(Number)</u>	<u>(Country)</u>	<u>(Foreign Filing Date)</u>	<u>Yes</u>	<u>No</u>
<u>(Number)</u>	<u>(Country)</u>	<u>(Foreign Filing Date)</u>	<u>Yes</u>	<u>No</u>

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

<u>60/258,760</u>	<u>December 30, 2000</u>
Application Number	(Filing Date)

_____	_____
Application Number	(Filing Date)

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

_____	_____	_____
Application Number	Filing Date	Status -- patented, pending, abandoned

_____	_____	_____
Application Number	Filing Date	Status -- patented, pending, abandoned

I hereby appoint the persons listed on Appendix A hereto (which is incorporated by reference and a part of this document) as my respective patent attorneys and patent agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith.

Send correspondence to Gregg A. Peacock, Reg. No. 45,001, BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN LLP, 12400 Wilshire Boulevard 7th Floor, Los Angeles, California 90025 and direct telephone calls to Gregg A. Peacock, Reg. No. 45,001, (512) 330-0844.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Sole/First Inventor David Stiles

Inventor's Signature David Stiles

Date 3/29/01

Residence Los Gatos, California

(City, State)

Citizenship USA

(Country)

Post Office Address 21108 Brush Road

Los Gatos, California 95033

Full Name of Joint/Second Inventor Gerald W. Neufeld

Inventor's Signature _____

Date _____

Residence Los Altos, CA 94024

(City, State)

Citizenship USA

(Country)

Post Office Address 675 Greenview Place

Los Altos, CA 94024

APPENDIX A

William E. Alford, Reg. No. 37,764; Farzad E. Amini, Reg. No. 42,261; William Thomas Babbitt, Reg. No. 39,591; Carol F. Barry, Reg. No. 41,600; Jordan Michael Becker, Reg. No. 39,602; Lisa N. Benado, Reg. No. 39,995; Bradley J. Berezna, Reg. No. 33,474; Michael A. Bernadicou, Reg. No. 35,934; Roger W. Blakely, Jr., Reg. No. 25,831; R. Alan Burnett, Reg. No. 46,149; Gregory D. Caldwell, Reg. No. 39,926; Thomas M. Coester, Reg. No. 39,637; Donna Jo Coningsby, Reg. No. 41,684; Florin Corie, Reg. No. 46,244; Dennis M. deGuzman, Reg. No. 41,702; Stephen M. De Klerk, Reg. No. 46,503; Michael Anthony DeSanctis, Reg. No. 39,957; Daniel M. De Vos, Reg. No. 37,813; Harish C. Dhingra, Reg. No. 38,856; Justin M. Dillon, Reg. No. 42,486; Sanjeet Dutta, Reg. No. 46,145; Matthew C. Fagan, Reg. No. 37,542; Tarek N. Fahmi, Reg. No. 41,402; George Fountain, Reg. No. 37,374; James Y. Go, Reg. No. 40,621; James A. Henry, Reg. No. 41,064; Libby N. Ho, Reg. No. 46,774; Willmore F. Holbrow III, Reg. No. 41,845; Sheryl Sue Holloway, Reg. No. 37,850; George W. Hoover II, Reg. No. 32,992; Eric S. Hyman, Reg. No. 30,139; William W. Kidd, Reg. No. 31,772; Sang Hui Kim, Reg. No. 40,450; Walter T. Kim, Reg. No. 42,731; Eric T. King, Reg. No. 44,188; George Brian Leavell, Reg. No. 45,436; Kurt P. Leyendecker, Reg. No. 42,799; Gordon R. Lindeen III, Reg. No. 33,192; Jan Carol Little, Reg. No. 41,181; Robert G. Litts, Reg. No. 46,876; Joseph Lutz, Reg. No. 43,765; Michael J. Mallie, Reg. No. 36,591; Andre L. Marais, under 37 C.F.R. § 10.9(b); Paul A. Mendonsa, Reg. No. 42,879; Clive D. Menezes, Reg. No. 45,493; Richard A. Nakashima, Reg. No. 42,023; Chun M. Ng, Reg. No. 36,878; Thien T. Nguyen, Reg. No. 43,835; Thinh V. Nguyen, Reg. No. 42,034; Dennis A. Nicholls, Reg. No. 42,036; Robert B. O'Rourke, Reg. No. 46,972; Daniel E. Ovanezian, Reg. No. 41,236; Kenneth B. Paley, Reg. No. 38,989; Gregg A. Peacock, Reg. No. 45,001; Marina Portnova, Reg. No. 45,750; William F. Ryann, Reg. No. 44,313; James H. Salter, Reg. No. 35,668; William W. Schaal, Reg. No. 39,018; James C. Scheller, Reg. No. 31,195; Jeffrey Schubert, Reg. No. 43,089; George P. Simion, Reg. No. 47,089; Jeffrey Sam Smith, Reg. No. 39,377; Maria McCormack Sobrino, Reg. No. 31,639; Stanley W. Sokoloff, Reg. No. 25,128; Judith A. Szepesi, Reg. No. 39,393; Vincent P. Tassinari, Reg. No. 42,179; Edwin H. Taylor, Reg. No. 25,129; John F. Travis, Reg. No. 43,203; Joseph A. Twarowski, Reg. No. 42,191; Tom Van Zandt, Reg. No. 43,219; Lester J. Vincent, Reg. No. 31,460; Glenn E. Von Tersch, Reg. No. 41,364; John Patrick Ward, Reg. No. 40,216; Mark L. Watson, Reg. No. 46,322; Thomas C. Webster, Reg. No. 46,154; and Norman Zafman, Reg. No. 26,250; my patent attorneys, and Firasat Ali, Reg. No. 45,715; Thomas S. Ferrill, Reg. No. 42,532; Charles P. Landrum, Reg. No. 46,855; and Raul Martinez, Reg. No. 46,904, my patent agents, of BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN LLP, with offices located at 12400 Wilshire Boulevard, 7th Floor, Los Angeles, California 90025, telephone (310) 207-3800, and James R. Thein, Reg. No. 31,710, my patent attorney with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith.

APPENDIX B

Title 37, Code of Federal Regulations, Section 1.56 Duty to Disclose Information Material to Patentability

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

- (1) Prior art cited in search reports of a foreign patent office in a counterpart application, and
- (2) The closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

(b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

- (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or
- (2) It refutes, or is inconsistent with, a position the applicant takes in:
 - (i) Opposing an argument of unpatentability relied on by the Office, or
 - (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

(c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:

- (1) Each inventor named in the application;
- (2) Each attorney or agent who prepares or prosecutes the application; and
- (3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.

(d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.